SAR402663 / Sanofi - LARVOL DELTA

A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - P1/2 | N=66 | Active, not recruiting | Sponsor: Sanofi | Recruiting ➔ Active, not recruiting

Enrollment closed • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Press Release: Sanofi’s SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration (GlobeNewswire) - "Sanofi is currently evaluating SAR402663 in a phase 1/2 (clinical study identifier: NCT06660667), for the treatment of patients with neovascular AMD."

Fast track • Wet Age-related Macular Degeneration